PureTech Advances LYT-200 In Blood Cancer Program After FDA Feedback, Fast Track Status

PureTech Health said the FDA completed its End-of-Phase 1 review for LYT-200 and granted Fast Track designation for treatment of relapsed/refractory high-risk myelodysplastic syndromes. The designation may accelerate development and regulatory engagement for the experimental therapy, representing a positive clinical and regulatory milestone for PureTech.